D-0721-2022 Class III Terminated
FDA drug recall D-0721-2022 was initiated by Olympia Compounding Pharmacy Dba Olympia Pharmacy on Mar 8, 2022 and is designated Class III. Reason for recall: Super Potent The recall status is terminated (terminated Oct 4, 2023). Affected quantity: 1093 vials.
Recall Details
- Product Type
- Drugs
- Report Date
- Mar 30, 2022
- Initiation Date
- Mar 8, 2022
- Termination Date
- Oct 4, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1093 vials
Product Description
T-105, Papaverine 30 mg/mL Phentolamine 1 mg/mL PGE 10 mcg/mL packaged as a) 5 mL Multi-dose NDC 73198-0005-05; b) 10 mL Multi-dose NDC 73198-0005-10; Each ML contains: 0.5% Chlorobutanol NF, 0.0005% Edetate Disodium Dihydrate USP, 1.84% Benzyl Alcohol NF, 5% Mannitol USP, 1% Sodium Metabisulfite NF, 0.5% Ethyl Alcohol USP, Sterile Water for Injection USP, Rx Only, Olympia Pharmaceuticals, 6700 Conroy Rd., Ste. 155, Orlando, FL 32835.
Reason for Recall
Super Potent
Distribution Pattern
Nationwide in the USA including Puerto Rico.
Code Information
Lots: a) E41F10 Exp. 5/10/22; b) E41G10 Exp. 5/10/22
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0721-2022
- openFDA file date
- Oct 23, 2026
- Loaded by RegDataLab
- Oct 25, 2026